Pharmaguy's Insights Into Drug Industry News
186.0K views | +14 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

@Richmeyer Rips Facebook a New One for Hosting Anti-Xarelto "Ambulance Chaser" Ads

@Richmeyer Rips Facebook a New One for Hosting Anti-Xarelto "Ambulance Chaser" Ads | Pharmaguy's Insights Into Drug Industry News | Scoop.it

According to the Times “If I were a Facebook executive, I might feel a Frankensteinian sense of unease these days. The company has been hit with a series of scandals that have bruised its image, enraged its critics and opened up the possibility that in its quest for global dominance, Facebook may have created something it can’t fully control.”  And they want pharma to advertise more?

As CEO of Facebook Mr. Zuckerberg’s modus operandi as a leader is to fix things long after they have broken , rather than to prevent problems in the first place.  For pharma that’s a major issue.

This is an ad that I keep seeing on Facebook as I was doing some research for a client.  I did an analysis of the comments and 85% were negative.  If I was a DTC manager or media buyer I would not proceed to give more money to the this monster.

Facebook has become some huge and profitable that they feel they can do no wrong.  They don’t have enough people with industry experience and their continued efforts to court pharma ad dollars is almost insulting.

Obviously Xarelto has risks, like any prescription drug, but hosting ads for ambulance chasers who profit off patient woes is is not a platform I would ever recommend to clients.

Pharma Guy's insight:

Still , this is less of a problem for me than hosting fake news ads/stories from Russian agents!

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Bayer/Janssen’s Xarelto COMPASS Trial Stopped Early - "Superior" to Aspirin But Without the Safety Profile

Bayer/Janssen’s Xarelto COMPASS Trial Stopped Early - "Superior" to Aspirin But Without the Safety Profile | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Bayer/Janssen's bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.

 

The 27,000-plus patient trial was scheduled to finish next year but has been stopped early on the advice of an independent Data Monitoring Committee, after the primary endpoint of prevention of MACE - including cardiovascular death, myocardial infarction and stroke - reached its pre-specified criteria for superiority versus aspirin.

 

Given the magnitude of the drug's effect, Janssen, Bayer and the Population Health Research Institute (PHRI), which collaborated on the study, said they will offer Xarelto (rivaroxaban) to study participants in an open-label extension trial.

 

"Despite established and effective treatments, incidences of CAD and PAD are rising globally," said Paul Burton, vice president, Medical Affairs, Janssen. "We are excited about the possibility of making rivaroxaban available to patients with CAD and PAD to reduce their risk of major adverse cardiac events, and look forward to discussing the COMPASS trial data with the US Food and Drug Administration as quickly as possible."

Pharma Guy's insight:

This article, which appears to be lifted directly from a press release, does not mention any of Xarelto's side effects. Johnson and Johnson and Bayer Corp. are being sued based on allegations that they deliberately concealed the blood thinner Xarelto potential fatal side effect of internal bleeding: http://sco.lt/6XbVHl  Meanwhile, AMA chastised lawyers for revealing Xarelto's side effects in TV Ads:  http://sco.lt/5RkA4X 

more...
No comment yet.